COMMUNIQUÉS West-GlobeNewswire

Hemab Therapeutics to Present Clinical and Preclinical Data from Multiple Blood Coagulation Programs at the ISTH 2026 Congress
26/06/2026
New results from HMB-002 first-in-human data validate proof of mechanism in Von Willebrand disease (VWD), elevating Von Willebrand Factor (VWF) and Factor VIII (FVIII) levels with subcutaneous dosing; multiple dose [...]
HCW Biologics Announces 1-for-6 Reverse Stock Split Effective on June 30, 2026
26/06/2026
Company completed 28 consecutive trading days above $1.00 per share on June 25, 2026 Reverse stock split effectuated to ensure ongoing compliance with the Bid Price Rule and additional requirements from Nasdaq Hearings [...]
Nkarta to Participate in H.C. Wainwright 4th Annual Cell Therapy Virtual Conference
26/06/2026
SOUTH SAN FRANCISCO, Calif., June 26, 2026 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat autoimmune [...]
CDT Highlights Sarborg's Application of Quantum Computing to Solid-Form Development
26/06/2026
NAPLES, Fla. and CAMBRIDGE, United Kingdom, June 26, 2026 (GLOBE NEWSWIRE) -- CDT Equity Inc. (Nasdaq: CDT) (“CDT” or the “Company”), today notes the announcement from Sarborg Limited regarding the expansion of its [...]
Thought Leadership & Innovation Foundation Founder Bill Oldham Launches New Book: Beyond Better Data: What Actually Changes Health Care?
26/06/2026
MCLEAN, Va., June 26, 2026 (GLOBE NEWSWIRE) -- The Thought Leadership & Innovation Foundation (TLI) proudly announces the release of Beyond Better Data: What Actually Changes Health Care? a new book by Founder and [...]
Capricor Therapeutics Announces FDA Advisory Committee Meeting to Review BLA for Deramiocel for the Treatment of Duchenne Muscular Dystrophy
26/06/2026
–Advisory Committee meeting scheduled for July 29, 2026– –Company's Biologics License Application on track with PDUFA target action date of August 22, 2026– SAN DIEGO, June 26, 2026 (GLOBE NEWSWIRE) -- Capricor [...]
Sienna Completes Acquisition in Greater Ottawa Area
26/06/2026
MARKHAM, Ontario, June 26, 2026 (GLOBE NEWSWIRE) -- Sienna Senior Living Inc. (" Sienna " or the " Company ") (TSX: SIA) announced today that it has completed its previously disclosed acquisition of Rockland Manor, a [...]
LIXTE Joins Russell Microcap Index
26/06/2026
BOCA RATON, Fla., June 26, 2026 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (“LIXTE” or the “Company”) (Nasdaq: LIXT), today announced its inclusion in the Russell Microcap ® Index, effective after the close [...]
Replimune Announces FDA Acceptance of RP1 Biologics License Application Resubmission for Advanced Melanoma
26/06/2026
FDA decision expected by August 2, 2026 WOBURN, Mass., June 26, 2026 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical-stage biotechnology company pioneering the development of novel oncolytic [...]
Vaxart Publishes Presentation Urging Shareholders to Vote “FOR” ALL Six of the Company’s Highly Qualified Director Nominees on the WHITE Proxy Card TODAY
26/06/2026
Details Strategic Actions Taken by the Board to Advance the Company’s Pipeline and Drive Value Creation Vaxart’s Purpose-Built Board Brings the Proven Expertise Needed to Oversee its Next Phase of Growth Dissident [...]
New Yorkers Celebrate Independence Through Helen Keller's Legacy at Premiere of Groundbreaking Documentary Possibilities
26/06/2026
Blind artists, educators, advocates, and creatives gather on Helen Keller's 146th birthday ahead of America's 250th anniversary NEW YORK, June 26, 2026 (GLOBE NEWSWIRE) -- As America approaches the 250th anniversary of [...]
CHMP recommendation advances Johnson & Johnson’s TECVAYLI®▼ (teclistamab) plus daratumumab as a potential standard of care for relapsed/refractory multiple myeloma
26/06/2026
Recommendation supported by unprecedented Phase 3 data, demonstrating that TECVAYLI ® in combination with daratumumab achieved statistically significant improvements in progression-free and overall survival versus [...]
Axsome Therapeutics Initiates FOCUS-3 Phase 3 Trial of Solriamfetol in Adolescents with Attention Deficit Hyperactivity Disorder (ADHD)
26/06/2026
NEW YORK, June 26, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced that the [...]
Tilray Medical Expands Medical Cannabis Access for Veterans Through Lyphe Clinic at Aldershot’s Armed Forces Weekend
26/06/2026
Lyphe Clinic, Tilray’s trusted medical cannabis clinic, will engage veterans, service members and families through its Lyphe for Veterans access programme. The Aldershot activation highlights Tilray Medical’s commitment [...]
Transcom Leading Voices Connects CX Executives Through Peer Learning
26/06/2026
Transcom opens Leading Voices, a platform of real-world advice from leaders working through AI adoption in customer experience. It pairs peer perspectives and learning tools with Transcom's own proven CX results, from [...]
Fortrea Names Jason Knoblauch as Chief Financial Officer
26/06/2026
Jason Knoblauch will succeed Jill McConnell as chief financial officer of Fortrea DURHAM, N.C., June 26, 2026 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE) (the “Company”), a leading global contract research organization ( [...]
Jade Biosciences Announces Appointment of Mark Eisner, M.D., M.P.H., to Board of Directors
26/06/2026
SAN FRANCISCO and VANCOUVER, British Columbia, June 26, 2026 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (the “Company” or “Jade”) (Nasdaq: JBIO), a clinical-stage biotechnology company focused on developing best-in- [...]
New Autism Research to be Presented at European Purine Scientific Meeting
26/06/2026
CALGARY, Alberta, June 26, 2026 (GLOBE NEWSWIRE) -- Marvel Biosciences Corp. (TSXV: MRVL | OTC: MBCOF ), and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively “Marvel” or the “Company” ), a drug [...]
Complex Small Molecules Are Changing Drug R&D
26/06/2026
Structural complexity in modern small molecules is reshaping what drug development partners must deliver from discovery through commercial supply. Targeted protein degraders, covalent agents, and a new wave of kinase [...]

Pages